Adam S Faye1, Kate E Lee2, Monika Laszkowska3, Judith Kim3, John William Blackett3, Anna S McKenney4, Anna Krigel3, Jon T Giles5, Runsheng Wang5, Elana J Bernstein5, Peter H R Green3, Suneeta Krishnareddy3, Chin Hur3, Benjamin Lebwohl3. 1. A.S. Faye, MD, MS, Department of Medicine, Division of Digestive and Liver Diseases, NewYork-Presbyterian/Columbia University Irving Medical Center, Department of Medicine, Henry D. Janowitz Division of Gastroenterology, Mount Sinai Hospital; adam.faye@mountsinai.org. 2. K.E. Lee, BA, Vagelos College of Physicians and Surgeons, Columbia University. 3. M. Laszkowska, MD, MS, J. Kim, MD, J.W. Blackett, MD, A. Krigel, MD, MS, P.H. Green, MD, S. Krishnareddy, MD, MS, C. Hur, MD, MPH, B. Lebwohl, MD, MS, Department of Medicine, Division of Digestive and Liver Diseases, NewYork-Presbyterian/Columbia University Irving Medical Center. 4. A.S. McKenney, MD, PhD, MPH, Department of Radiology, NewYork-Presbyterian/Weill Cornell Medical College. 5. J.T. Giles, MD, MPH, R. Wang, MD, MHS, E.J. Bernstein, MD, MSc, Department of Medicine, Division of Rheumatology, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
Abstract
OBJECTIVE: To examine the effect of autoimmune (AI) disease on the composite outcome of intensive care unit (ICU) admission, intubation, or death from COVID-19 in hospitalized patients. METHODS: Retrospective cohort study of 186 patients hospitalized with COVID-19 between March 1, 2020, and April 15, 2020 at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center. The cohort included 62 patients with AI disease and 124 age- and sex-matched controls. The primary outcome was a composite of ICU admission, intubation, and death, with secondary outcome as time to in-hospital death. Baseline demographics, comorbidities, medications, vital signs, and laboratory values were collected. Conditional logistic regression and Cox proportional hazards regression were used to assess the association between AI disease and clinical outcomes. RESULTS: Patients with AI disease were more likely to have at least one comorbidity (87.1% vs 74.2%, P = 0.04), take chronic immunosuppressive medications (66.1% vs 4.0%, P < 0.01), and have had a solid organ transplant (16.1% vs 1.6%, P < 0.01). There were no significant differences in ICU admission (13.7% vs 19.4%, P = 0.32), intubation (13.7% vs 17.7%, P = 0.47), or death (16.1% vs 14.5%, P = 0.78). On multivariable analysis, patients with AI disease were not at an increased risk for a composite outcome of ICU admission, intubation, or death (ORadj 0.79, 95% CI 0.37-1.67). On Cox regression, AI disease was not associated with in-hospital mortality (HRadj 0.73, 95% CI 0.33-1.63). CONCLUSION: Among patients hospitalized with COVID-19, individuals with AI disease did not have an increased risk of a composite outcome of ICU admission, intubation, or death.
OBJECTIVE: To examine the effect of autoimmune (AI) disease on the composite outcome of intensive care unit (ICU) admission, intubation, or death from COVID-19 in hospitalized patients. METHODS: Retrospective cohort study of 186 patients hospitalized with COVID-19 between March 1, 2020, and April 15, 2020 at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center. The cohort included 62 patients with AI disease and 124 age- and sex-matched controls. The primary outcome was a composite of ICU admission, intubation, and death, with secondary outcome as time to in-hospital death. Baseline demographics, comorbidities, medications, vital signs, and laboratory values were collected. Conditional logistic regression and Cox proportional hazards regression were used to assess the association between AI disease and clinical outcomes. RESULTS: Patients with AI disease were more likely to have at least one comorbidity (87.1% vs 74.2%, P = 0.04), take chronic immunosuppressive medications (66.1% vs 4.0%, P < 0.01), and have had a solid organ transplant (16.1% vs 1.6%, P < 0.01). There were no significant differences in ICU admission (13.7% vs 19.4%, P = 0.32), intubation (13.7% vs 17.7%, P = 0.47), or death (16.1% vs 14.5%, P = 0.78). On multivariable analysis, patients with AI disease were not at an increased risk for a composite outcome of ICU admission, intubation, or death (ORadj 0.79, 95% CI 0.37-1.67). On Cox regression, AI disease was not associated with in-hospital mortality (HRadj 0.73, 95% CI 0.33-1.63). CONCLUSION: Among patients hospitalized with COVID-19, individuals with AI disease did not have an increased risk of a composite outcome of ICU admission, intubation, or death.
Authors: Saurabh Aggarwal; Nelson Garcia-Telles; Gaurav Aggarwal; Carl Lavie; Giuseppe Lippi; Brandon Michael Henry Journal: Diagnosis (Berl) Date: 2020-05-26
Authors: Jennifer Lighter; Michael Phillips; Sarah Hochman; Stephanie Sterling; Diane Johnson; Fritz Francois; Anna Stachel Journal: Clin Infect Dis Date: 2020-07-28 Impact factor: 9.079
Authors: Alberto Zangrillo; Luigi Beretta; Anna Mara Scandroglio; Giacomo Monti; Evgeny Fominskiy; Sergio Colombo; Federica Morselli; Alessandro Belletti; Paolo Silvani; Martina Crivellari; Fabrizio Monaco; Maria Luisa Azzolini; Raffaella Reineke; Pasquale Nardelli; Marianna Sartorelli; Carmine D Votta; Annalisa Ruggeri; Fabio Ciceri; Francesco De Cobelli; Moreno Tresoldi; Lorenzo Dagna; Patrizia Rovere-Querini; Ary Serpa Neto; Rinaldo Bellomo; Giovanni Landoni Journal: Crit Care Resusc Date: 2020-09 Impact factor: 2.159
Authors: Erica J Brenner; Ryan C Ungaro; Richard B Gearry; Gilaad G Kaplan; Michele Kissous-Hunt; James D Lewis; Siew C Ng; Jean-Francois Rahier; Walter Reinisch; Frank M Ruemmele; Flavio Steinwurz; Fox E Underwood; Xian Zhang; Jean-Frederic Colombel; Michael D Kappelman Journal: Gastroenterology Date: 2020-05-18 Impact factor: 22.682
Authors: Jose L Pablos; María Galindo; Loreto Carmona; Ana Lledó; Miriam Retuerto; Ricardo Blanco; Miguel A Gonzalez-Gay; David Martinez-Lopez; Isabel Castrejón; José M Alvaro-Gracia; David Fernández Fernández; Antonio Mera-Varela; Sara Manrique-Arija; Natalia Mena Vázquez; Antonio Fernandez-Nebro Journal: Ann Rheum Dis Date: 2020-08-12 Impact factor: 19.103
Authors: Juan C Sarmiento-Monroy; Gerard Espinosa; Maria-Carlota Londoño; Fernanda Meira; Berta Caballol; Sara Llufriu; Josep Lluis Carrasco; Aina Moll-Udina; Luis F Quintana; Priscila Giavedoni; Julio Ramírez; Jose Inciarte-Mundo; Elisabeth Solana; Yolanda Blanco; Eugenia Martinez-Hernandez; Maria Sepúlveda; Victor Llorenç; Sergio Prieto-González; Georgina Espígol-Frigolé; Jose C Milisenda; Maria C Cid; Jose M Mascaró; Isabel Blanco; Joan Albert Barberá; Oriol Sibila; Jordi Gratacos-Ginès; Alfredo Adán; Alvaro Agustí; Raimon Sanmartí; Julian Panés; Ricard Cervera; Jordi Vila; Alex Soriano; José A Gómez-Puerta Journal: J Autoimmun Date: 2020-11-30 Impact factor: 7.094
Authors: Emily F N Yuki; Eduardo F Borba; Sandra G Pasoto; Luciana P Seguro; Michelle Lopes; Carla G S Saad; Ana Cristina Medeiros-Ribeiro; Clovis A Silva; Danieli C O de Andrade; Leonard de Vinci K Kupa; Lorena Betancourt; Isabela Bertoglio; Juliana Valim; Camilla Hoff; Francisco F C Formiga; Tatiana Pedrosa; Esper G Kallas; Nadia E Aikawa; Eloisa Bonfa Journal: Arthritis Care Res (Hoboken) Date: 2022-03-04 Impact factor: 5.178
Authors: Gabriel Figueroa-Parra; Emily L Gilbert; Maria O Valenzuela-Almada; Sebastian Vallejo; Matthew R Neville; Naomi J Patel; Claire Cook; Xiaoqing Fu; Ramla Hagi; Gregory C McDermott; Michael A Dilorio; Lucy Masto; Kathleen M M Vanni; Emily Kowalski; Grace Qian; Yuqing Zhang; Zachary S Wallace; Alí Duarte-García; Jeffrey A Sparks Journal: Lancet Rheumatol Date: 2022-09-13
Authors: Benjamin Lebwohl; Emma Larsson; Jonas Söderling; Bjorn Roelstraete; Joseph A Murray; Peter H R Green; Jonas F Ludvigsson Journal: Clin Epidemiol Date: 2021-02-18 Impact factor: 4.790